Opsonic antibodies to staphylococcus epidermidis: In vitro and in vivo studies using human intravenous immune globulin

Gerald W. Fischer, Theodore J. Cieslak, Samuel R. Wilson, Leonard E. Weisman, Val G. Hemming

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Staphylococcus epidermidis is a major cause of nosocomial infections, including sepsis in premature infants. Intravenous immune globulin (IVIG) has been used to prevent neonatal sepsis, but efficacy has varied in different clinical trials. The role of IgG antibody in immunity to S. epidermidis was studied using an opsonophagocytic assay and a lipid-emulsion-induced lethal model of neonatal S. epidermidis sepsis. Opsonic antibody to S. epidermidis varied between IVIG preparations and between lots: Lots with ≥90% opsonic activity promoted bacterial clearance from blood and significantly enhanced survival when compared with lots with ≤50% opsonic activity. Absorption of IVIG with S. epidermidis removed in vitro opsonic and in vivo protective activity. These studies suggest that opsonic antibody may play an important role inS. epidermidis immunity in immunocompromised patients, such as premature infants. Standard IVIG, however, may not provide therapy effective in preventing S. epidermidis infections, as many IVIG lots contain insufficient levels of opsonic S. epidermidis antibody.

Original languageEnglish (US)
Pages (from-to)324-329
Number of pages6
JournalJournal of Infectious Diseases
Volume169
Issue number2
DOIs
StatePublished - Feb 1994

Fingerprint

Staphylococcus epidermidis
Intravenous Immunoglobulins
Antibodies
Premature Infants
Immunity
Sepsis
Immunocompromised Host
Cross Infection
In Vitro Techniques
Emulsions
Immunoglobulin G
Clinical Trials
Lipids
Infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Opsonic antibodies to staphylococcus epidermidis : In vitro and in vivo studies using human intravenous immune globulin. / Fischer, Gerald W.; Cieslak, Theodore J.; Wilson, Samuel R.; Weisman, Leonard E.; Hemming, Val G.

In: Journal of Infectious Diseases, Vol. 169, No. 2, 02.1994, p. 324-329.

Research output: Contribution to journalArticle

Fischer, Gerald W. ; Cieslak, Theodore J. ; Wilson, Samuel R. ; Weisman, Leonard E. ; Hemming, Val G. / Opsonic antibodies to staphylococcus epidermidis : In vitro and in vivo studies using human intravenous immune globulin. In: Journal of Infectious Diseases. 1994 ; Vol. 169, No. 2. pp. 324-329.
@article{c39d09253b584713bafdf3d13fab1eed,
title = "Opsonic antibodies to staphylococcus epidermidis: In vitro and in vivo studies using human intravenous immune globulin",
abstract = "Staphylococcus epidermidis is a major cause of nosocomial infections, including sepsis in premature infants. Intravenous immune globulin (IVIG) has been used to prevent neonatal sepsis, but efficacy has varied in different clinical trials. The role of IgG antibody in immunity to S. epidermidis was studied using an opsonophagocytic assay and a lipid-emulsion-induced lethal model of neonatal S. epidermidis sepsis. Opsonic antibody to S. epidermidis varied between IVIG preparations and between lots: Lots with ≥90{\%} opsonic activity promoted bacterial clearance from blood and significantly enhanced survival when compared with lots with ≤50{\%} opsonic activity. Absorption of IVIG with S. epidermidis removed in vitro opsonic and in vivo protective activity. These studies suggest that opsonic antibody may play an important role inS. epidermidis immunity in immunocompromised patients, such as premature infants. Standard IVIG, however, may not provide therapy effective in preventing S. epidermidis infections, as many IVIG lots contain insufficient levels of opsonic S. epidermidis antibody.",
author = "Fischer, {Gerald W.} and Cieslak, {Theodore J.} and Wilson, {Samuel R.} and Weisman, {Leonard E.} and Hemming, {Val G.}",
year = "1994",
month = "2",
doi = "10.1093/infdis/169.2.324",
language = "English (US)",
volume = "169",
pages = "324--329",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Opsonic antibodies to staphylococcus epidermidis

T2 - In vitro and in vivo studies using human intravenous immune globulin

AU - Fischer, Gerald W.

AU - Cieslak, Theodore J.

AU - Wilson, Samuel R.

AU - Weisman, Leonard E.

AU - Hemming, Val G.

PY - 1994/2

Y1 - 1994/2

N2 - Staphylococcus epidermidis is a major cause of nosocomial infections, including sepsis in premature infants. Intravenous immune globulin (IVIG) has been used to prevent neonatal sepsis, but efficacy has varied in different clinical trials. The role of IgG antibody in immunity to S. epidermidis was studied using an opsonophagocytic assay and a lipid-emulsion-induced lethal model of neonatal S. epidermidis sepsis. Opsonic antibody to S. epidermidis varied between IVIG preparations and between lots: Lots with ≥90% opsonic activity promoted bacterial clearance from blood and significantly enhanced survival when compared with lots with ≤50% opsonic activity. Absorption of IVIG with S. epidermidis removed in vitro opsonic and in vivo protective activity. These studies suggest that opsonic antibody may play an important role inS. epidermidis immunity in immunocompromised patients, such as premature infants. Standard IVIG, however, may not provide therapy effective in preventing S. epidermidis infections, as many IVIG lots contain insufficient levels of opsonic S. epidermidis antibody.

AB - Staphylococcus epidermidis is a major cause of nosocomial infections, including sepsis in premature infants. Intravenous immune globulin (IVIG) has been used to prevent neonatal sepsis, but efficacy has varied in different clinical trials. The role of IgG antibody in immunity to S. epidermidis was studied using an opsonophagocytic assay and a lipid-emulsion-induced lethal model of neonatal S. epidermidis sepsis. Opsonic antibody to S. epidermidis varied between IVIG preparations and between lots: Lots with ≥90% opsonic activity promoted bacterial clearance from blood and significantly enhanced survival when compared with lots with ≤50% opsonic activity. Absorption of IVIG with S. epidermidis removed in vitro opsonic and in vivo protective activity. These studies suggest that opsonic antibody may play an important role inS. epidermidis immunity in immunocompromised patients, such as premature infants. Standard IVIG, however, may not provide therapy effective in preventing S. epidermidis infections, as many IVIG lots contain insufficient levels of opsonic S. epidermidis antibody.

UR - http://www.scopus.com/inward/record.url?scp=0027976735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027976735&partnerID=8YFLogxK

U2 - 10.1093/infdis/169.2.324

DO - 10.1093/infdis/169.2.324

M3 - Article

C2 - 8106765

AN - SCOPUS:0027976735

VL - 169

SP - 324

EP - 329

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -